Document is current

Article History

Received: 18 September 2023

Accepted: 26 June 2024

First Online: 11 July 2024

Competing interests

: Potential conflicts of interest are the following: F.B-M. reports patents filed: PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369, and part time employment by Reveal Genomics. C.F. is currently employed by AstraZeneca. O.M-S. reports travel expenses and consulting fees from Roche, AstraZeneca and Reveal Genomics and speaker fees from Eisai, Novartis and Daiichi. J.M.C. reports travel expenses and speaker fees from AstraZeneca, Lilly, Pfizer, Gilead, Novartis and MSD. R.S-B. has received travel grants from Pfizer, Astra Zeneca, and Novartis, and honoraria for speaker or advisory board participation from Novartis, Lilly, Astra Zeneca, Daiichi Sankyo, Roche, Glaxo Smith Kline, Clovis Oncology, Seagen, and Accord. R.S.-B. non-financial interests include European Society of Medical Oncology Young Oncologists Committee member, Spanish Society of Medical Oncology—Scientific Secretary. G.V. has received a speaker’s fee from MSD, Pfizer, GSK and Pierre Fabrer, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics. E.C. reports advisory and consulting fees or speaker honoraria from Roche, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, Menarini, MSD, Novartis, Gilead, and Reveal Genomics, institutional financial interests from Roche, Pfizer, travel grants from Roche, Pfizer, AstraZeneca, Daiichi Sankyo, and non-financial steering committee member for Roche, Astra Zeneca, Daiichi Sankyo, Novartis, Reveal Genomics. S.P. reports travel grants from Gilead, Roche, Astra-Zeneca, and Pfizer, and honoraria for speaker or advisory board participation from SeaGen, Novartis, Lilly, Pfizer, Astra Zeneca-Daiichi, Roche, and Gilead. J.C, reports speaker honoraria or advisory and consulting fees from Glaxo, AstraZeneca, Roche, Novartis, Pharmamar, Eisai, Lilly, Pierre Fabre, Daichii Sankyo, Seagen, Deciphera and Pfizer and travel grants from Gilead, Astra Zeneca, Daichii Sankyo, Roche, Novartis, Pharmamar. A.P. reports consulting fees from Roche, Novartis, AstraZeneca, Daiichi-Sankyo, and Peptomyc; patents filed PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369; stockholder and consultant of Reveal Genomics; and institutional financial interests from Roche, Novartis, AstraZeneca, Daiichi-Sankyo, Reveal Genomics, Ona Therapeutics, BMS, and Pfizer. M.O. reports institutional grant/research from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, Gilead, GSK, Immutep, Roche, Seagen, Zenith Epigenetics, advisory and consulting fees or speaker honoraria from AstraZeneca, Cureos Science, Daiichi-Sankyo/AstraZeneca, Gilead, iTEOS, Lilly, MSD, Relay Therapeutics, Roche, Seagen, Eisai, Libbs, Novartis, Pfizer, travel grants from AstraZeneca, Eisai, Gilead, Pierre-Fabre, and non-financial disclosure as the SOLTI Breast Cancer Group president elected. The remaining authors declare no competing interests.